inositol has been researched along with Insulin Resistance in 158 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study strove to investigate the hypothesis that a low dosage of myo-inositol supplementation might decrease the likelihood of gestational diabetes in overweight, pregnant women." | 9.69 | The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial. ( Basirat, Z; Delavar, MA; Esmaeilzadeh, S; Ghadimi, R; Mashayekh-Amiri, S, 2023) |
| "To compare the effect of myo-inositol and d-chiro-inositol in combination (MI + DCI) with combined hormonal contraceptive (CHC) on menstrual cycle regulation in young Indian women with polycystic ovary syndrome (PCOS)." | 9.51 | Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study. ( Bhatla, N; Kachhawa, G; Khadgawat, R; Kulshrestha, V; Mahey, R; Senthil Kumar, KV, 2022) |
| "To compare the effects of insulin sensitizers metformin (MET) and myo-inositol (MI) on adiponectin levels and metabolic characteristics in women with polycystic ovary syndrome (PCOS) with respect to their body mass index (BMI)." | 9.51 | The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. ( Bjekić-Macut, J; Livadas, S; Macut, D; Malešević, G; Mastorakos, G; Micić, D; Ognjanović, S; Popović-Pejičić, S; Prtina, A; Soldat-Stanković, V; Stanković, S, 2022) |
| "To verify whether myo-inositol plus α-lactalbumin may reduce insulin resistance and excessive fetal growth in women with gestational diabetes mellitus." | 9.41 | Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study. ( Corrado, F; D'Anna, R; Di Benedetto, A; Giunta, L; Gullo, G; Loddo, S, 2021) |
| "This trial will provide evidence for the effectiveness of myo-inositol supplementation during pregnancy in reducing the incidence of gestational diabetes mellitus." | 9.34 | Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: study protocol for a randomized controlled trial. ( Anastasiou, E; Antsaklis, P; Asimakopoulos, G; Daskalakis, G; Kallergi, A; Loutradis, D; Pergialiotis, V; Sindos, M; Theodora, M; Vogiatzi, E, 2020) |
| "To improve insulin sensitivity, insulin-sensitizing drugs such as metformin are commonly used in overweight and obese T1D patients." | 9.24 | A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. ( Defeudis, G; Del Toro, R; Fioriti, E; Guglielmi, C; Kyanvash, S; Maggi, D; Manfrini, S; Maurizi, AR; Menduni, M; Pantano, AL; Pozzilli, P, 2017) |
| "This study assessed the effects of an inositol-enriched beverage (IEB) on blood glucose levels and inflammation status in subjects with an impaired fasting glucose (IFG) state according to body mass index (BMI)." | 9.22 | Effect of consumption of a carob pod inositol-enriched beverage on insulin sensitivity and inflammation in middle-aged prediabetic subjects. ( Bañuls, C; Hernández-Mijares, A; López-Doménech, S; Rocha, M; Rovira-Llopis, S; Veses, S; Víctor, VM, 2016) |
| "The aim of the present study is to evaluate the effectiveness of myo-inositol alone or in combination with clomiphene citrate for (1) induction of ovulation and (2) pregnancy rate in anovulatory women with PCOS and proven insulin resistance." | 9.20 | Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. ( Carlomagno, G; Gateva, A; Genazzani, AD; Kamenov, Z; Kolarov, G, 2015) |
| "Inositol has been reported to improve insulin sensitivity since it works as a second messenger achieving insulin-like effects on metabolic enzymes." | 9.17 | Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. ( Botti, G; Brillante, G; Capasso, I; Cavalcanti, E; Ciliberto, G; Crispo, A; D'Aiuto, G; D'Aiuto, M; De Laurentiis, M; Esposito, E; Esposito, G; Frasci, G; Fucito, A; Grimaldi, M; Maurea, N; Montella, M, 2013) |
| "To test the hypothesis that dietary myo-inositol may improve insulin resistance and the development of gestational diabetes mellitus (GDM) in women at high risk of this disorder." | 9.17 | Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. ( Celentano, C; D'Angelo, M; Liberati, M; Matarrelli, B; Mattei, PA; Pavone, G; Vitacolonna, E, 2013) |
| "To evaluate the effects the administration of myo-inositol (MYO) on hormonal parameters in a group of polycystic ovary syndrome (PCOS) patients." | 9.17 | Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. ( Artini, PG; Cela, V; Di Berardino, OM; Genazzani, AD; Papini, F; Ruggiero, M; Simi, G, 2013) |
| "To evaluate the 12-month effect of myo-inositol treatment on some biochemical parameters of women affected by metabolic syndrome." | 9.16 | One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. ( Benedetto, AD; Corrado, F; D'Anna, R; Giordano, D; Interdonato, ML; Pintaudi, B; Santamaria, A; Vieste, GD, 2012) |
| "The aim of this study was to evaluate whether myo-inositol, an insulin-sensitizing substance, may improve some features of metabolic syndrome in postmenopausal women." | 9.15 | Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. ( Corrado, F; D'Anna, R; Di Benedetto, A; Giordano, D; Pintaudi, B; Quattrone, S; Santamaria, A, 2011) |
| "To test the hypothesis that myoinositol supplementation will improve insulin sensitivity as measured by markers of insulin resistance such as homeostasis model assessment of insulin resistance and adiponectin in women with gestational diabetes." | 9.15 | The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. ( Corrado, F; D'Anna, R; Di Benedetto, A; Di Vieste, G; Giordano, D; Pintaudi, B; Santamaria, A, 2011) |
| "Compare the effects of a combined contraceptive pill (OCP) in combination with myo-inositol (MI) on endocrine, metabolic, and clinical parameters in patients with polycystic ovary syndrome (PCOS)." | 9.15 | The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. ( Costantino, D; Guaraldi, C; Minozzi, M; Unfer, V, 2011) |
| "The aim of this review is to present the current data about the role of inositols in the management of polycystic ovary syndrome (PCOS) women and in the prevention and treatment of gestational diabetes mellitus (GDM)." | 8.98 | The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review. ( Gateva, A; Kamenov, Z; Unfer, V, 2018) |
| " Insulin-sensitising agents such as metformin may be effective in treating PCOS-related anovulation." | 8.95 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E, 2017) |
| "During the last decades, a substantial body of research has focused on the role of the two major inositol (Ins) stereoisomers, myoinositol (myoIns) and D-chiroinositol (D-chiroIns), both second messengers of insulin, in insulin-dependent processes, including polycystic ovary syndrome (PCOS)." | 8.93 | Physiological role and clinical utility of inositols in polycystic ovary syndrome. ( Bevilacqua, A; Bizzarri, M, 2016) |
| "In agreement with the previous review, metformin was associated with improved clinical pregnancy but there was no evidence that metformin improves live birth rates whether it is used alone or in combination with clomiphene, or when compared with clomiphene." | 8.88 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2012) |
| "In agreement with the previous review, metformin is still of benefit in improving clinical pregnancy and ovulation rates." | 8.86 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2010) |
| " Both metformin and myo-inositol were found to improve insulin sensitivity and to reduce thyrotropin levels in individuals with hypothyroidism." | 8.12 | Differences in levothyroxine action on thyroid autoimmunity and hypothalamic-pituitary-thyroid axis activity between metformin- and myo-inositol-treated women with autoimmune subclinical hypothyroidism. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "Vitamin D and myo-inositol reduce thyroid antibody titers in subjects with autoimmune thyroiditis." | 8.12 | The impact of vitamin D on thyroid autoimmunity and hypothalamic-pituitary-thyroid axis activity in myo-inositol-treated and myo-inositol-naïve women with autoimmune thyroiditis: A pilot study. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "Myo-inositol supplementation may reduce insulin resistance (IR) with few serious side effects in patients with polycystic ovary syndrome (PCOS)." | 7.96 | Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model. ( Chen, X; Li, C; Zhang, W; Zhang, Y; Zheng, X, 2020) |
| "The aim of this retrospective study was to evaluate the effects of a long-term treatment with α-lipoic acid (ALA) combined with myo-inositol (MI) on clinical and metabolic features of women with polycystic ovary syndrome (PCOS)." | 7.96 | Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome. ( Fidecicchi, T; Fruzzetti, F; Gambacciani, M; Palla, G, 2020) |
| "To evaluate the effects of the combination of d-chiro inositol and alpha lipoic acid on menstrual cycles and insulin sensitivity in women with polycystic ovary syndrome (PCOS)." | 7.91 | Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome. ( Canu, A; Capozzi, A; Fruzzetti, F; Lello, S, 2019) |
| "d- chiro-Inositol (DCI) is a biologically active component found in tartary buckwheat, which can reduce hyperglycemia and ameliorate insulin resistance." | 7.91 | d- chiro-Inositol Ameliorates High Fat Diet-Induced Hepatic Steatosis and Insulin Resistance via PKCε-PI3K/AKT Pathway. ( Cheng, F; Ge, X; Han, L; Li, Y; Pan, C; Wang, M; Xiao, Y; Yan, S; Zhang, Y, 2019) |
| "The aim of our study was to investigate the effects of a combined treatment with alpha-lipoic acid (ALA) and myoinositol (MYO) on clinical, endocrine and metabolic features of women affected by polycystic ovary syndrome (PCOS)." | 7.85 | Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. ( Apa, R; De Cicco, S; Della Casa, S; Di Florio, C; Immediata, V; Lanzone, A; Policola, C; Romualdi, D; Scarinci, E; Tagliaferri, V; Tropea, A, 2017) |
| "Myoinositol and D-chiroinositol improve insulin resistance in women with obesity and gestational diabetes and in postmenopausal women with metabolic syndrome." | 7.83 | The effect of combined inositol supplementation on maternal metabolic profile in pregnancies complicated by metabolic syndrome and obesity. ( Blackwell, SC; Facchinetti, F; Ferrari, F; Longo, M; Ontiveros, AE; Refuerzo, JS; Roberts, RP; Saade, MM; Sibai, BM, 2016) |
| "In recent years, interest has been focused to the study of the two major inositol stereoisomers: myo-inositol (MI) and d-chiro-inositol (DCI), because of their involvement, as second messengers of insulin, in several insulin-dependent processes, such as metabolic syndrome and polycystic ovary syndrome." | 7.81 | Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS. ( Benvenga, S; Bevilacqua, A; Bizzarri, M; Carlomagno, G; Cavalli, P; Chiu, TT; D'Anna, R; Devroey, P; Di Renzo, GC; Facchinetti, F; Gerli, S; Hod, M; Kamenov, ZA; Lanzone, A; Oliva, MM; Soulage, C, 2015) |
| "Previous studies from our and other labs have shown that insulin resistance is associated with an inositol imbalance of excess myo-inositol and deficient chiro-inositol together with a deficiency of myo-inositol to chiro-inositol epimerase in vivo and in vitro." | 7.80 | Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. ( Heimark, D; Larner, J; McAllister, J, 2014) |
| "Phytic acid, also known as myo-inositol hexaphosphate, has been shown to lower blood glucose levels and to improve insulin sensitivity in rodents." | 7.80 | Phytic acid and myo-inositol support adipocyte differentiation and improve insulin sensitivity in 3T3-L1 cells. ( Han, SN; Kim, HK; Kim, JN, 2014) |
| "In an attempt to evaluate the role of inositol supplementation in insulin-resistant patients with polycystic ovary syndrome (PCOS), undergoing gonadotropin ovulation induction using the low-dose step-down regimen, we conducted a prospective longitudinal study comparing the stimulation characteristics of 15 patients treated with inositol, to a cohort, matched by age and body mass index (BMI), without inositol." | 7.77 | The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. ( De Leo, V; Di Sabatino, A; Morgante, G; Musacchio, MC; Orvieto, R, 2011) |
| "To assess this possibility in polycystic ovary syndrome (PCOS), we determined insulin sensitivity (Si by frequently sampled intravenous glucose tolerance test), plasma and urinary DCI and myo-inositol (MYO) levels (by gas chromatography/mass spectrometry), and the release of insulin and DCI-IPG during the oral glucose tolerance test (area under the curve [AUC]) in 23 women with PCOS and 26 normal women." | 7.73 | Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. ( Apridonidze, T; Baillargeon, JP; Diamanti-Kandarakis, E; Iuorno, MJ; Nestler, JE; Ostlund, RE, 2006) |
| " We studied whether pretreatment with these compounds can prevent the deleterious effects of glucosamine on insulin action that may play an important role in hyperglycemia-induced insulin resistance." | 7.70 | Differential effects of troglitazone and D-chiroinositol on glucosamine-induced insulin resistance in vivo in rats. ( Hattori, J; Kawachi, S; Nakashima, K; Okumura, S; Sasaki, A; Sugimoto, M; Takami, K; Takami, R; Takeda, N; Yasuda, K; Yoshino, K, 1999) |
| "To determine the relationship between urinary chiro-inositol excretion and insulin sensitivity in Japanese type II diabetic patients." | 7.69 | Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes. ( Hinokio, Y; Hirai, A; Hirai, M; Hirai, S; Kawasaki, H; Matsumoto, M; Ohtomo, M; Onoda, M; Satoh, Y; Suzuki, S, 1994) |
| "The acute effects of administration of D-chiroinositol (D-CI), a component of a putative mediator of insulin action, on plasma glucose were examined in low dose streptozotocin-treated rats and normal rats given a glucose load and the effects on plasma glucose and insulin were determined in five obese rhesus monkeys with varying degrees of spontaneous insulin resistance." | 7.68 | Chiroinositol deficiency and insulin resistance. II. Acute effects of D-chiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin-resistant rhesus monkeys. ( Hansen, BC; Huang, LC; Larner, J; Ortmeyer, HK; Zhang, L, 1993) |
| " On such basis, we investigated the efficacy on insulin sensitivity and hormonal parameters of 8 weeks treatment with myo-inositol (MYO) (Inofert, ItalPharmaco, Milano, Italy) at the dosage of 2 g day in a group (n = 42) of obese PCOS patients,." | 6.77 | Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. ( Artini, PG; Campedelli, A; Chierchia, E; Genazzani, AD; Prati, A; Rattighieri, E; Ricchieri, F; Santagni, S; Simoncini, T, 2012) |
| "Pregnancy is characterized by a physiologic increase in insulin resistance, which, associated with increased oxidative stress and inflammations, could induce alterations of glucose metabolism and diabetes." | 6.61 | Inositol and antioxidant supplementation: Safety and efficacy in pregnancy. ( Baldassarre, MPA; Bucci, I; Carlucci, MA; Consoli, A; Formoso, G; Ginestra, F, 2019) |
| "Inositol is a polyalcohol, naturally occurring as nine stereoisomers, including D-chiro-inositol (DCI) and myo-inositol (MI), which have prominent roles in the metabolism of glucose and free fatty acids." | 6.53 | Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. ( Brady, DM; Laganà, AS; Maniglio, P; Paul, C; Triolo, O, 2016) |
| "This study strove to investigate the hypothesis that a low dosage of myo-inositol supplementation might decrease the likelihood of gestational diabetes in overweight, pregnant women." | 5.69 | The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial. ( Basirat, Z; Delavar, MA; Esmaeilzadeh, S; Ghadimi, R; Mashayekh-Amiri, S, 2023) |
| "To compare the effect of myo-inositol and d-chiro-inositol in combination (MI + DCI) with combined hormonal contraceptive (CHC) on menstrual cycle regulation in young Indian women with polycystic ovary syndrome (PCOS)." | 5.51 | Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study. ( Bhatla, N; Kachhawa, G; Khadgawat, R; Kulshrestha, V; Mahey, R; Senthil Kumar, KV, 2022) |
| "To compare the effects of insulin sensitizers metformin (MET) and myo-inositol (MI) on adiponectin levels and metabolic characteristics in women with polycystic ovary syndrome (PCOS) with respect to their body mass index (BMI)." | 5.51 | The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. ( Bjekić-Macut, J; Livadas, S; Macut, D; Malešević, G; Mastorakos, G; Micić, D; Ognjanović, S; Popović-Pejičić, S; Prtina, A; Soldat-Stanković, V; Stanković, S, 2022) |
| "Polycystic ovary syndrome is characterized by several endocrine impairments, insulin resistance and hyperinsulinemia." | 5.51 | Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. ( Genazzani, AD; Marchini, F; Napolitano, A; Petrillo, T; Prati, A; Simoncini, T, 2019) |
| "Evidence from seven studies shows that antenatal dietary supplementation with myo-inositol during pregnancy may reduce the incidence of gestational diabetes, hypertensive disorders of pregnancy and preterm birth." | 5.41 | Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes. ( Alsweiler, J; Crawford, TJ; Crowther, CA; Lin, L; Motuhifonua, SK, 2023) |
| "To verify whether myo-inositol plus α-lactalbumin may reduce insulin resistance and excessive fetal growth in women with gestational diabetes mellitus." | 5.41 | Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study. ( Corrado, F; D'Anna, R; Di Benedetto, A; Giunta, L; Gullo, G; Loddo, S, 2021) |
| "Some inositol isomers have been reported to possess insulin-mimetic activity and to be efficient in lowering blood glucose level." | 5.39 | Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice. ( Croze, ML; Guichardant, M; Hadji, L; Pillon, NJ; Soula, HA; Soulage, CO; Vella, RE, 2013) |
| "Thus, compensatory hyperinsulinemia might suppress renal clearance of DCI to increase plasma DCI levels and partially compensate for insulin resistance by improving DCI availability in men." | 5.35 | Hyperinsulinemia is closely related to low urinary clearance of D-chiro-inositol in men with a wide range of insulin sensitivity. ( Baillargeon, JP; Ostlund, RE; Villeneuve, MC, 2009) |
| "This trial will provide evidence for the effectiveness of myo-inositol supplementation during pregnancy in reducing the incidence of gestational diabetes mellitus." | 5.34 | Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: study protocol for a randomized controlled trial. ( Anastasiou, E; Antsaklis, P; Asimakopoulos, G; Daskalakis, G; Kallergi, A; Loutradis, D; Pergialiotis, V; Sindos, M; Theodora, M; Vogiatzi, E, 2020) |
| "As in humans, monkeys with NIDDM have a lower urinary excretion rate of chiroinositol (CI), a component of a putative mediator of insulin action, compared to normal monkeys." | 5.29 | Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys. ( Bodkin, NL; Hansen, BC; Larner, J; Lilley, K; Ortmeyer, HK, 1993) |
| " The aim of the study is to compare the effect of different dosages of inositol stereoisomers supplementation on insulin resistance levels and several maternal-fetal outcomes in GDM women." | 5.27 | Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial. ( Celentano, C; Di Nicola, M; Di Vieste, G; Franzago, M; Fraticelli, F; Liberati, M; Pintaudi, B; Vitacolonna, E; Zecca, IA, 2018) |
| "Linagliptin modestly improves glycemic profile in patients with well controlled T2DM; however, it may not have an effect on insulin sensitivity in these patients." | 5.27 | Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial. ( Bhansali, A; Bhansali, S; Bhat, K; Kurpad, AV; Parthan, G; Walia, R, 2018) |
| "To improve insulin sensitivity, insulin-sensitizing drugs such as metformin are commonly used in overweight and obese T1D patients." | 5.24 | A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. ( Defeudis, G; Del Toro, R; Fioriti, E; Guglielmi, C; Kyanvash, S; Maggi, D; Manfrini, S; Maurizi, AR; Menduni, M; Pantano, AL; Pozzilli, P, 2017) |
| " Many studies have reported improvement in insulin resistance and thereby intracellular glucose uptake after myo-inositol treatment in PCOS patients, but these studies have a small sample size, varying methodology, and outcome analysis." | 5.22 | Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial. ( Deshpande, S; Gajjar, N; Jethaliya, H; Patel, R; Patel, V, 2022) |
| "To date, the involvement of α-Lactalbumin (α-LA) in the management of polycystic ovary syndrome (PCOS) refers to its ability to improve intestinal absorption of natural molecules like inositols, overcoming the inositol resistance." | 5.22 | Positive Effects of α-Lactalbumin in the Management of Symptoms of Polycystic Ovary Syndrome. ( Artale, S; Basciani, S; Bizzarri, M; Cardinale, V; Lepore, E; Nordio, M; Unfer, V, 2022) |
| "This study assessed the effects of an inositol-enriched beverage (IEB) on blood glucose levels and inflammation status in subjects with an impaired fasting glucose (IFG) state according to body mass index (BMI)." | 5.22 | Effect of consumption of a carob pod inositol-enriched beverage on insulin sensitivity and inflammation in middle-aged prediabetic subjects. ( Bañuls, C; Hernández-Mijares, A; López-Doménech, S; Rocha, M; Rovira-Llopis, S; Veses, S; Víctor, VM, 2016) |
| "The aim of the present study is to evaluate the effectiveness of myo-inositol alone or in combination with clomiphene citrate for (1) induction of ovulation and (2) pregnancy rate in anovulatory women with PCOS and proven insulin resistance." | 5.20 | Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. ( Carlomagno, G; Gateva, A; Genazzani, AD; Kamenov, Z; Kolarov, G, 2015) |
| "Our study showed that both myo-inositol (MI-PG) and D-chiro inositol (DCI-PG) treatments are able to significantly improve the regularity of the menstrual cycle, the Acne Score, the endocrine and metabolic parameters and the insulin-resistence in young, overweight, PCOS patients." | 5.20 | Myo-inositol vs. D-chiro inositol in PCOS treatment. ( Ciotta, L; Formuso, C; Stracquadanio, M, 2015) |
| "This new myo-inositol, monacolin K and lipoic acid association contains appropriate substances to contrast various etiopathogenic elements responsible for the onset of PCOS and the symptoms of hyperandrogenism and dyslipidemia related to it." | 5.20 | Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association. ( Cappelli, V; De Leo, V; Di Sabatino, A; Massaro, MG; Morgante, G, 2015) |
| "Myo-inositol and D-chiro-inositol are capable of improving the ovarian function and metabolism of polycystic ovary syndrome (PCOS) patients." | 5.19 | Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. ( Barbaro, L; Laganà, AS; Pizzo, A, 2014) |
| " Since it has been demonstrated a high incidence of insulin resistance in PCOS patients, our study aimed to evaluate the efficacy of the integrative treatment with D-chiro-inositol (DCI) (500 mg die, per os, for 12 weeks) on hormonal parameters and insulin sensitivity in a group of overweight/obese PCOS patients (body mass index; BMI > 26)." | 5.19 | Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. ( Chierchia, E; Despini, G; Genazzani, AD; Marini, G; Prati, A; Rattighieri, E; Santagni, S; Simoncini, T, 2014) |
| " Aim of the study was to evaluate the efficacy of natural substances such as inositol and glucomannan, and their combination in reducing glucose levels and improving insulin sensitivity in PCOS patients." | 5.19 | [Combination inositol and glucomannan in PCOS patients]. ( Cappelli, V; Cianci, EA; De Leo, V; Morgante, G; Tosti, C, 2014) |
| "Inositol has been reported to improve insulin sensitivity since it works as a second messenger achieving insulin-like effects on metabolic enzymes." | 5.17 | Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. ( Botti, G; Brillante, G; Capasso, I; Cavalcanti, E; Ciliberto, G; Crispo, A; D'Aiuto, G; D'Aiuto, M; De Laurentiis, M; Esposito, E; Esposito, G; Frasci, G; Fucito, A; Grimaldi, M; Maurea, N; Montella, M, 2013) |
| "To test the hypothesis that dietary myo-inositol may improve insulin resistance and the development of gestational diabetes mellitus (GDM) in women at high risk of this disorder." | 5.17 | Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. ( Celentano, C; D'Angelo, M; Liberati, M; Matarrelli, B; Mattei, PA; Pavone, G; Vitacolonna, E, 2013) |
| "To evaluate the effects the administration of myo-inositol (MYO) on hormonal parameters in a group of polycystic ovary syndrome (PCOS) patients." | 5.17 | Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. ( Artini, PG; Cela, V; Di Berardino, OM; Genazzani, AD; Papini, F; Ruggiero, M; Simi, G, 2013) |
| "To evaluate the 12-month effect of myo-inositol treatment on some biochemical parameters of women affected by metabolic syndrome." | 5.16 | One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. ( Benedetto, AD; Corrado, F; D'Anna, R; Giordano, D; Interdonato, ML; Pintaudi, B; Santamaria, A; Vieste, GD, 2012) |
| "The aim of this study was to evaluate whether myo-inositol, an insulin-sensitizing substance, may improve some features of metabolic syndrome in postmenopausal women." | 5.15 | Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. ( Corrado, F; D'Anna, R; Di Benedetto, A; Giordano, D; Pintaudi, B; Quattrone, S; Santamaria, A, 2011) |
| "To test the hypothesis that myoinositol supplementation will improve insulin sensitivity as measured by markers of insulin resistance such as homeostasis model assessment of insulin resistance and adiponectin in women with gestational diabetes." | 5.15 | The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. ( Corrado, F; D'Anna, R; Di Benedetto, A; Di Vieste, G; Giordano, D; Pintaudi, B; Santamaria, A, 2011) |
| "Compare the effects of a combined contraceptive pill (OCP) in combination with myo-inositol (MI) on endocrine, metabolic, and clinical parameters in patients with polycystic ovary syndrome (PCOS)." | 5.15 | The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. ( Costantino, D; Guaraldi, C; Minozzi, M; Unfer, V, 2011) |
| "We reviewed current literature in different databases, searching for D-chiro-Inositol in relation with one of the following keywords: myo-inositol, PCOS, infertility, insulin resistance, aromatase, androgen and inositol, testosterone, estrogen and inositol, estradiol, hypogonadotropic hypogonadism, fat tissue, estrogens and cancer, anovulation, uterine myoma, endometriosis, endometrial hyperplasia." | 5.12 | The use of D-chiro-Inositol in clinical practice. ( Aragona, C; Bevilacqua, A; Bizzarri, M; Forte, G; Gambioli, R; Unfer, V, 2021) |
| "Ours is the first study to report that for women with PCOS, myo-inositol combined with D-chiro-inositol and metformin combined with thiazolidinediones appear superior to metformin alone in improving insulin resistance and decreasing total testosterone." | 5.12 | Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. ( He, B; Xing, C; Zhang, J; Zhao, H, 2021) |
| " We conclude that plasma levels of both pinitol and D-chiro-inositol are very responsive to pinitol ingestion, but insulin sensitivity does not increase after pinitol treatment in individuals with obesity and mild type 2 diabetes." | 5.09 | Effect of pinitol treatment on insulin action in subjects with insulin resistance. ( Christiansen, M; Davis, A; Hellerstein, MK; Horowitz, JF; Klein, S; Ostlund, RE, 2000) |
| "Inositol supplementation decreases blood glucose through an improvement in insulin sensitivity that is independent of weight." | 5.01 | Effects of inositol on glucose homeostasis: Systematic review and meta-analysis of randomized controlled trials. ( Corcoy, R; Cuixart, G; Gonçalves, A; Miñambres, I, 2019) |
| "The aim of this review is to present the current data about the role of inositols in the management of polycystic ovary syndrome (PCOS) women and in the prevention and treatment of gestational diabetes mellitus (GDM)." | 4.98 | The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review. ( Gateva, A; Kamenov, Z; Unfer, V, 2018) |
| " The vast majority of published data on insulin sensitizing PCOS treatments are reported in adult women; these have included weight loss, metformin, thiazolidinediones, and the inositols." | 4.95 | Insulin sensitizers in adolescents with polycystic ovary syndrome. ( LE, TN; Nestler, JE; Wickham, EP, 2017) |
| " Insulin-sensitising agents such as metformin may be effective in treating PCOS-related anovulation." | 4.95 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E, 2017) |
| "During the last decades, a substantial body of research has focused on the role of the two major inositol (Ins) stereoisomers, myoinositol (myoIns) and D-chiroinositol (D-chiroIns), both second messengers of insulin, in insulin-dependent processes, including polycystic ovary syndrome (PCOS)." | 4.93 | Physiological role and clinical utility of inositols in polycystic ovary syndrome. ( Bevilacqua, A; Bizzarri, M, 2016) |
| "In agreement with the previous review, metformin was associated with improved clinical pregnancy but there was no evidence that metformin improves live birth rates whether it is used alone or in combination with clomiphene, or when compared with clomiphene." | 4.88 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2012) |
| "In agreement with the previous review, metformin is still of benefit in improving clinical pregnancy and ovulation rates." | 4.86 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2010) |
| "The obtained results suggest that myo-inositol supplementation potentiates the inhibitory effect of metformin on prolactin levels in women with hyperprolactinemia." | 4.31 | Myo-Inositol Potentiates the Inhibitory Effect of Metformin on Prolactin Levels. ( Basiak, M; Krysiak, R; Okopień, B; Szkróbka, W, 2023) |
| " Both metformin and myo-inositol were found to improve insulin sensitivity and to reduce thyrotropin levels in individuals with hypothyroidism." | 4.12 | Differences in levothyroxine action on thyroid autoimmunity and hypothalamic-pituitary-thyroid axis activity between metformin- and myo-inositol-treated women with autoimmune subclinical hypothyroidism. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "Vitamin D and myo-inositol reduce thyroid antibody titers in subjects with autoimmune thyroiditis." | 4.12 | The impact of vitamin D on thyroid autoimmunity and hypothalamic-pituitary-thyroid axis activity in myo-inositol-treated and myo-inositol-naïve women with autoimmune thyroiditis: A pilot study. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "This study, conducted at a university-affiliated medical center, included two groups of postmenopausal women with prediabetes, matched for age, FSH and LH levels, and insulin sensitivity: women taking myo-inositol preparations for at least 6 months (group A, n = 23) and women not receiving inositol preparations (group B, n = 23)." | 4.12 | Myo-Inositol Enhances the Inhibitory Effect of Metformin on Gonadotropin Levels in Postmenopausal Women. ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "Myo-inositol supplementation at physiological doses during lactation improves metabolic health and prevents the programmed trend to develop insulin resistance and hypertriglyceridemia in male rats acquired by inadequate fetal nutrition and exacerbated by a diabetogenic diet in adulthood." | 4.02 | Sex-Specific Effects of Myo-Inositol Ingested During Lactation in the Improvement of Metabolic Health in Adult Rats. ( Castillo, P; Núñez, P; Otero, D; Palou, A; Palou, M; Picó, C, 2021) |
| " In the last years, among the insulin sensitizers, the use of the two active isoforms of inositols (myo-inositol and d-chiro-inositol) has been spreading for the treatment of PCOS insulin resistance." | 4.02 | The relevance of inositols treatment for PCOS before and during ART. ( Artini, PG; Genazzani, AD; Malacarne, E; Tomatis, V, 2021) |
| "Myo-inositol supplementation may reduce insulin resistance (IR) with few serious side effects in patients with polycystic ovary syndrome (PCOS)." | 3.96 | Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model. ( Chen, X; Li, C; Zhang, W; Zhang, Y; Zheng, X, 2020) |
| "The insulin resistance state of pancreatic α-cells seems to be related to glucagon hypersecretion in type 2 diabetes." | 3.96 | Direct Effects of D-Chiro-Inositol on Insulin Signaling and Glucagon Secretion of Pancreatic Alpha Cells. ( Di Mauro, S; Di Pino, A; Filippello, A; Malaguarnera, R; Piro, S; Purrello, F; Scamporrino, A; Scicali, R, 2020) |
| "The aim of this retrospective study was to evaluate the effects of a long-term treatment with α-lipoic acid (ALA) combined with myo-inositol (MI) on clinical and metabolic features of women with polycystic ovary syndrome (PCOS)." | 3.96 | Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome. ( Fidecicchi, T; Fruzzetti, F; Gambacciani, M; Palla, G, 2020) |
| "To evaluate the effects of the combination of d-chiro inositol and alpha lipoic acid on menstrual cycles and insulin sensitivity in women with polycystic ovary syndrome (PCOS)." | 3.91 | Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome. ( Canu, A; Capozzi, A; Fruzzetti, F; Lello, S, 2019) |
| "d- chiro-Inositol (DCI) is a biologically active component found in tartary buckwheat, which can reduce hyperglycemia and ameliorate insulin resistance." | 3.91 | d- chiro-Inositol Ameliorates High Fat Diet-Induced Hepatic Steatosis and Insulin Resistance via PKCε-PI3K/AKT Pathway. ( Cheng, F; Ge, X; Han, L; Li, Y; Pan, C; Wang, M; Xiao, Y; Yan, S; Zhang, Y, 2019) |
| "The aim of our study was to investigate the effects of a combined treatment with alpha-lipoic acid (ALA) and myoinositol (MYO) on clinical, endocrine and metabolic features of women affected by polycystic ovary syndrome (PCOS)." | 3.85 | Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. ( Apa, R; De Cicco, S; Della Casa, S; Di Florio, C; Immediata, V; Lanzone, A; Policola, C; Romualdi, D; Scarinci, E; Tagliaferri, V; Tropea, A, 2017) |
| "Myoinositol and D-chiroinositol improve insulin resistance in women with obesity and gestational diabetes and in postmenopausal women with metabolic syndrome." | 3.83 | The effect of combined inositol supplementation on maternal metabolic profile in pregnancies complicated by metabolic syndrome and obesity. ( Blackwell, SC; Facchinetti, F; Ferrari, F; Longo, M; Ontiveros, AE; Refuerzo, JS; Roberts, RP; Saade, MM; Sibai, BM, 2016) |
| "We previously reported that a chronic supplementation with myo-inositol (MI) improved insulin sensitivity and reduced fat accretion in mice." | 3.81 | Abnormalities in myo-inositol metabolism associated with type 2 diabetes in mice fed a high-fat diet: benefits of a dietary myo-inositol supplementation. ( Croze, ML; Géloën, A; Soulage, CO, 2015) |
| "In recent years, interest has been focused to the study of the two major inositol stereoisomers: myo-inositol (MI) and d-chiro-inositol (DCI), because of their involvement, as second messengers of insulin, in several insulin-dependent processes, such as metabolic syndrome and polycystic ovary syndrome." | 3.81 | Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS. ( Benvenga, S; Bevilacqua, A; Bizzarri, M; Carlomagno, G; Cavalli, P; Chiu, TT; D'Anna, R; Devroey, P; Di Renzo, GC; Facchinetti, F; Gerli, S; Hod, M; Kamenov, ZA; Lanzone, A; Oliva, MM; Soulage, C, 2015) |
| "Previous studies from our and other labs have shown that insulin resistance is associated with an inositol imbalance of excess myo-inositol and deficient chiro-inositol together with a deficiency of myo-inositol to chiro-inositol epimerase in vivo and in vitro." | 3.80 | Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. ( Heimark, D; Larner, J; McAllister, J, 2014) |
| "Phytic acid, also known as myo-inositol hexaphosphate, has been shown to lower blood glucose levels and to improve insulin sensitivity in rodents." | 3.80 | Phytic acid and myo-inositol support adipocyte differentiation and improve insulin sensitivity in 3T3-L1 cells. ( Han, SN; Kim, HK; Kim, JN, 2014) |
| "In an attempt to evaluate the role of inositol supplementation in insulin-resistant patients with polycystic ovary syndrome (PCOS), undergoing gonadotropin ovulation induction using the low-dose step-down regimen, we conducted a prospective longitudinal study comparing the stimulation characteristics of 15 patients treated with inositol, to a cohort, matched by age and body mass index (BMI), without inositol." | 3.77 | The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. ( De Leo, V; Di Sabatino, A; Morgante, G; Musacchio, MC; Orvieto, R, 2011) |
| "To assess this possibility in polycystic ovary syndrome (PCOS), we determined insulin sensitivity (Si by frequently sampled intravenous glucose tolerance test), plasma and urinary DCI and myo-inositol (MYO) levels (by gas chromatography/mass spectrometry), and the release of insulin and DCI-IPG during the oral glucose tolerance test (area under the curve [AUC]) in 23 women with PCOS and 26 normal women." | 3.73 | Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. ( Apridonidze, T; Baillargeon, JP; Diamanti-Kandarakis, E; Iuorno, MJ; Nestler, JE; Ostlund, RE, 2006) |
| " We studied whether pretreatment with these compounds can prevent the deleterious effects of glucosamine on insulin action that may play an important role in hyperglycemia-induced insulin resistance." | 3.70 | Differential effects of troglitazone and D-chiroinositol on glucosamine-induced insulin resistance in vivo in rats. ( Hattori, J; Kawachi, S; Nakashima, K; Okumura, S; Sasaki, A; Sugimoto, M; Takami, K; Takami, R; Takeda, N; Yasuda, K; Yoshino, K, 1999) |
| "Troglitazone (T) and d-chiroinositol (DCI) have been reported to improve insulin resistance associated with obesity and NIDDM." | 3.70 | Pharmacological treatments for GH-induced insulin resistance. ( Hattori, J; Ishimori, M; Nakashima, K; Okumura, S; Sugimoto, M; Takeda, N; Yasuda, K; Yoshino, K, 1999) |
| "To determine the relationship between urinary chiro-inositol excretion and insulin sensitivity in Japanese type II diabetic patients." | 3.69 | Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes. ( Hinokio, Y; Hirai, A; Hirai, M; Hirai, S; Kawasaki, H; Matsumoto, M; Ohtomo, M; Onoda, M; Satoh, Y; Suzuki, S, 1994) |
| "The acute effects of administration of D-chiroinositol (D-CI), a component of a putative mediator of insulin action, on plasma glucose were examined in low dose streptozotocin-treated rats and normal rats given a glucose load and the effects on plasma glucose and insulin were determined in five obese rhesus monkeys with varying degrees of spontaneous insulin resistance." | 3.68 | Chiroinositol deficiency and insulin resistance. II. Acute effects of D-chiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin-resistant rhesus monkeys. ( Hansen, BC; Huang, LC; Larner, J; Ortmeyer, HK; Zhang, L, 1993) |
| "A total of 66 patients with type 2 diabetes who had been taking oral hypoglycemic agents for at least 3 months were enrolled and randomized to receive pinitol (n = 33) or matching placebo (n = 33)." | 2.77 | Effects of pinitol on glycemic control, insulin resistance and adipocytokine levels in patients with type 2 diabetes mellitus. ( Han, KA; Kim, HJ; Kim, YK; Ku, BJ; Lee, SK; Min, KW; Park, KS, 2012) |
| " On such basis, we investigated the efficacy on insulin sensitivity and hormonal parameters of 8 weeks treatment with myo-inositol (MYO) (Inofert, ItalPharmaco, Milano, Italy) at the dosage of 2 g day in a group (n = 42) of obese PCOS patients,." | 2.77 | Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. ( Artini, PG; Campedelli, A; Chierchia, E; Genazzani, AD; Prati, A; Rattighieri, E; Ricchieri, F; Santagni, S; Simoncini, T, 2012) |
| "The pioglitazone was effective in reducing plasma glucose and HbA1c from the baseline levels from Week 4 onward." | 2.73 | Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis. ( Abe, M; Kaizu, K; Kikuchi, F; Matsumoto, K, 2007) |
| "Insulin resistance is becoming an increasingly studied target for therapy, most evidence stemming from the time-honored metformin use." | 2.66 | Current treatment for polycystic ovary syndrome: focus on adolescence. ( Catellani, C; Cirillo, F; Dauriz, M; Lazzeroni, P; Moghetti, P; Sartori, C; Street, ME, 2020) |
| "Pregnancy is characterized by a physiologic increase in insulin resistance, which, associated with increased oxidative stress and inflammations, could induce alterations of glucose metabolism and diabetes." | 2.61 | Inositol and antioxidant supplementation: Safety and efficacy in pregnancy. ( Baldassarre, MPA; Bucci, I; Carlucci, MA; Consoli, A; Formoso, G; Ginestra, F, 2019) |
| "Inositol has been proposed as a food supplement that might reduce gestational diabetes incidence in high-risk pregnant women." | 2.53 | Myo-Inositol Supplementation to Prevent Gestational Diabetes Mellitus. ( Celentano, C; Liberati, M; Matarrelli, B; Mattei, PA; Pavone, G; Vitacolonna, E, 2016) |
| "Inositol is a polyalcohol, naturally occurring as nine stereoisomers, including D-chiro-inositol (DCI) and myo-inositol (MI), which have prominent roles in the metabolism of glucose and free fatty acids." | 2.53 | Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. ( Brady, DM; Laganà, AS; Maniglio, P; Paul, C; Triolo, O, 2016) |
| "Inositol is an organic compound of high biological importance that is widely distributed in nature." | 2.53 | Inositol and human reproduction. From cellular metabolism to clinical use. ( Czyzyk, A; Genazzani, AD; Meczekalski, B; Milewska, EM, 2016) |
| "Postprandial hyperglycemia is frequently associated with visceral obesity which plays a key role in metabolic abnormalities such as dyslipidemia and hypertension." | 2.42 | [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus]. ( Yamada, K, 2003) |
| "Myo-inositol (MYO) is an insulin-sensitizing compound used in PCOS patients; however, its insulin-sensitizing mechanism is unclear." | 1.56 | The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment. ( Cabrera-Cruz, H; Oróstica, L; Plaza-Parrochia, F; Romero, C; Torres-Pinto, I; Vega, M, 2020) |
| "Polycystic ovary syndrome is characterized by several endocrine impairments, insulin resistance and hyperinsulinemia." | 1.51 | Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. ( Genazzani, AD; Marchini, F; Napolitano, A; Petrillo, T; Prati, A; Simoncini, T, 2019) |
| "In this investigation, a model of type 2 diabetes mellitus (T2DM) was used on Sprague-Dawley (SD) rats to clarify more details of the mechanism in the therapy of T2DM." | 1.43 | Hypoglycemic effect of D-chiro-inositol in type 2 diabetes mellitus rats through the PI3K/Akt signaling pathway. ( Ai, RD; Gao, YF; Wang, TX; Wu, TC; Zhang, MN; Zhang, ZS, 2016) |
| "In this investigation, a model of type 2 diabetes mellitus (T2DM) with insulin resistance was established by feeding a high-fat diet (HFD) and injecting streptozocin (STZ) to Sprague-Dawley (SD) rats, targeting the exploration of more details of the mechanism in the therapy of T2DM." | 1.42 | Effects of D-Pinitol on Insulin Resistance through the PI3K/Akt Signaling Pathway in Type 2 Diabetes Mellitus Rats. ( Cai, H; Gao, Y; Wu, T; Xu, M; Zhang, M; Zhang, Z, 2015) |
| "We tested whether long-term administration of voglibose (VO) prevents diet induced obesity in addition to hypoglycemic effects in high fat fed mice and further investigated the underlying mechanisms by which voglibose exerts its weight lowering effect." | 1.40 | Voglibose administration regulates body weight and energy intake in high fat-induced obese mice. ( Chung, JH; Do, HJ; Hwang, JW; Jin, T; Shin, MJ, 2014) |
| "Some inositol isomers have been reported to possess insulin-mimetic activity and to be efficient in lowering blood glucose level." | 1.39 | Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice. ( Croze, ML; Guichardant, M; Hadji, L; Pillon, NJ; Soula, HA; Soulage, CO; Vella, RE, 2013) |
| "Thus, compensatory hyperinsulinemia might suppress renal clearance of DCI to increase plasma DCI levels and partially compensate for insulin resistance by improving DCI availability in men." | 1.35 | Hyperinsulinemia is closely related to low urinary clearance of D-chiro-inositol in men with a wide range of insulin sensitivity. ( Baillargeon, JP; Ostlund, RE; Villeneuve, MC, 2009) |
| " Increasing the bioavailability of arginine, the precursor of nitric oxide, thus potentially offers protection against end-stage disease." | 1.34 | Metabolic effects of a novel silicate inositol complex of the nitric oxide precursor arginine in the obese insulin-resistant JCR:LA-cp rat. ( Kelly, SE; Proctor, SD; Russell, JC; Vine, DF, 2007) |
| "As in humans, monkeys with NIDDM have a lower urinary excretion rate of chiroinositol (CI), a component of a putative mediator of insulin action, compared to normal monkeys." | 1.29 | Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys. ( Bodkin, NL; Hansen, BC; Larner, J; Lilley, K; Ortmeyer, HK, 1993) |
| "Inositol is a major component of the intracellular mediators of insulin action." | 1.28 | Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. ( Bogardus, C; Craig, J; Hansen, BC; Hill, CR; Kennington, AS; Larner, J; Ortmeyer, HK; Raz, I; Romero, G, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 20 (12.66) | 18.2507 |
| 2000's | 15 (9.49) | 29.6817 |
| 2010's | 80 (50.63) | 24.3611 |
| 2020's | 43 (27.22) | 2.80 |
| Authors | Studies |
|---|---|
| Kachhawa, G | 1 |
| Senthil Kumar, KV | 1 |
| Kulshrestha, V | 1 |
| Khadgawat, R | 1 |
| Mahey, R | 1 |
| Bhatla, N | 1 |
| Soldat-Stanković, V | 1 |
| Popović-Pejičić, S | 1 |
| Stanković, S | 1 |
| Prtina, A | 1 |
| Malešević, G | 1 |
| Bjekić-Macut, J | 1 |
| Livadas, S | 1 |
| Ognjanović, S | 1 |
| Mastorakos, G | 1 |
| Micić, D | 1 |
| Macut, D | 1 |
| Molonia, MS | 1 |
| Occhiuto, C | 1 |
| Muscarà, C | 1 |
| Speciale, A | 1 |
| Ruberto, G | 1 |
| Siracusa, L | 1 |
| Cristani, M | 1 |
| Saija, A | 1 |
| Cimino, F | 1 |
| DiNicolantonio, JJ | 1 |
| H O'Keefe, J | 1 |
| Laganà, AS | 5 |
| Monti, N | 1 |
| Fedeli, V | 2 |
| Gullo, G | 2 |
| Bizzarri, M | 9 |
| Amaefule, CE | 1 |
| Drymoussi, Z | 1 |
| Gonzalez Carreras, FJ | 1 |
| Pardo Llorente, MDC | 1 |
| Lanz, D | 1 |
| Dodds, J | 1 |
| Sweeney, L | 1 |
| Pizzo, E | 1 |
| Thomas, A | 1 |
| Heighway, J | 1 |
| Daru, J | 1 |
| Sobhy, S | 1 |
| Poston, L | 1 |
| Khalil, A | 1 |
| Myers, J | 1 |
| Harden, A | 1 |
| Hitman, G | 1 |
| Khan, KS | 1 |
| Zamora, J | 1 |
| Pérez, T | 1 |
| Huda, MSB | 1 |
| Thangaratinam, S | 1 |
| Jethaliya, H | 1 |
| Gajjar, N | 1 |
| Patel, V | 1 |
| Deshpande, S | 1 |
| Patel, R | 1 |
| López-Gambero, AJ | 1 |
| Pacheco-Sánchez, B | 1 |
| Rosell-Valle, C | 2 |
| Medina-Vera, D | 2 |
| Navarro, JA | 2 |
| Fernández-Arjona, MDM | 1 |
| de Ceglia, M | 1 |
| Sanjuan, C | 2 |
| Simon, V | 1 |
| Cota, D | 1 |
| Rivera, P | 1 |
| Rodríguez de Fonseca, F | 2 |
| Suárez, J | 1 |
| Esmaeilzadeh, S | 1 |
| Ghadimi, R | 1 |
| Mashayekh-Amiri, S | 1 |
| Delavar, MA | 1 |
| Basirat, Z | 1 |
| Unfer, V | 14 |
| Krysiak, R | 5 |
| Kowalcze, K | 4 |
| Okopień, B | 5 |
| Cardinale, V | 1 |
| Lepore, E | 2 |
| Basciani, S | 1 |
| Artale, S | 1 |
| Nordio, M | 1 |
| Moslehi, N | 1 |
| Zeraattalab-Motlagh, S | 1 |
| Rahimi Sakak, F | 1 |
| Shab-Bidar, S | 1 |
| Tehrani, FR | 1 |
| Mirmiran, P | 1 |
| Basiak, M | 1 |
| Szkróbka, W | 1 |
| Motuhifonua, SK | 1 |
| Lin, L | 1 |
| Alsweiler, J | 1 |
| Crawford, TJ | 1 |
| Crowther, CA | 1 |
| Catizone, A | 1 |
| Querqui, A | 1 |
| Guarnieri, G | 1 |
| Iervolino, M | 2 |
| Cavallone, S | 1 |
| Vianello, A | 1 |
| Mukherjee, S | 1 |
| Chakraborty, M | 1 |
| Haubner, J | 1 |
| Ernst, G | 1 |
| DePasquale, M | 1 |
| Carpenter, D | 1 |
| Barrow, JC | 1 |
| Chakraborty, A | 2 |
| Nazirudeen, R | 1 |
| Sridhar, S | 1 |
| Priyanka, R | 1 |
| Sumathi, B | 1 |
| Natarajan, V | 1 |
| Subbiah, E | 1 |
| Raghavan, KS | 1 |
| Sangumani, J | 1 |
| Guarano, A | 1 |
| Capozzi, A | 2 |
| Cristodoro, M | 1 |
| Di Simone, N | 1 |
| Lello, S | 2 |
| Plows, JF | 1 |
| Ramos Nieves, JM | 1 |
| Budin, F | 1 |
| Mace, K | 1 |
| Reynolds, CM | 1 |
| Vickers, MH | 1 |
| Silva-Zolezzi, I | 1 |
| Baker, PN | 1 |
| Stanley, JL | 1 |
| Cabrera-Cruz, H | 1 |
| Oróstica, L | 1 |
| Plaza-Parrochia, F | 1 |
| Torres-Pinto, I | 1 |
| Romero, C | 1 |
| Vega, M | 1 |
| Sobota-Grzeszyk, A | 1 |
| Kuźmicki, M | 1 |
| Szamatowicz, J | 1 |
| Zhang, Y | 2 |
| Li, C | 1 |
| Zhang, W | 1 |
| Zheng, X | 1 |
| Chen, X | 1 |
| Kısa, B | 1 |
| Sert, UY | 1 |
| Celik, HK | 1 |
| Candar, T | 1 |
| Erol Koç, EM | 1 |
| Taşcı, Y | 1 |
| Çağlar, GS | 1 |
| Street, ME | 1 |
| Cirillo, F | 1 |
| Catellani, C | 1 |
| Dauriz, M | 1 |
| Lazzeroni, P | 1 |
| Sartori, C | 1 |
| Moghetti, P | 1 |
| Asimakopoulos, G | 1 |
| Pergialiotis, V | 1 |
| Anastasiou, E | 1 |
| Antsaklis, P | 1 |
| Theodora, M | 1 |
| Vogiatzi, E | 1 |
| Kallergi, A | 1 |
| Sindos, M | 1 |
| Loutradis, D | 1 |
| Daskalakis, G | 1 |
| De Diego, MV | 1 |
| Gómez-Pardo, O | 1 |
| Groar, JK | 1 |
| López-Escobar, A | 1 |
| Martín-Estal, I | 1 |
| Castilla-Cortázar, I | 1 |
| Rodríguez-Zambrano, MÁ | 1 |
| Filippello, A | 1 |
| Scamporrino, A | 1 |
| Di Mauro, S | 1 |
| Malaguarnera, R | 1 |
| Di Pino, A | 1 |
| Scicali, R | 1 |
| Purrello, F | 1 |
| Piro, S | 1 |
| Pani, A | 1 |
| Giossi, R | 1 |
| Menichelli, D | 1 |
| Fittipaldo, VA | 1 |
| Agnelli, F | 1 |
| Inglese, E | 1 |
| Romandini, A | 1 |
| Roncato, R | 1 |
| Pintaudi, B | 5 |
| Del Sole, F | 1 |
| Scaglione, F | 1 |
| Genazzani, A | 1 |
| Liu, X | 1 |
| Li, SP | 1 |
| Gambioli, R | 1 |
| Forte, G | 2 |
| Aragona, C | 1 |
| Bevilacqua, A | 4 |
| Castillo, P | 1 |
| Palou, M | 1 |
| Otero, D | 1 |
| Núñez, P | 1 |
| Palou, A | 1 |
| Picó, C | 1 |
| D'Anna, R | 5 |
| Corrado, F | 4 |
| Loddo, S | 1 |
| Giunta, L | 1 |
| Di Benedetto, A | 3 |
| Buzzaccarini, G | 1 |
| Tovar, R | 1 |
| Gutiérrez-Adan, A | 1 |
| Ledesma, JC | 1 |
| Pavón, FJ | 1 |
| Baixeras, E | 1 |
| Decara, J | 1 |
| Cheng, F | 2 |
| Yun, SJ | 1 |
| Cao, JL | 1 |
| Chang, MC | 1 |
| Meng, JL | 1 |
| Liu, JY | 1 |
| Cheng, YF | 1 |
| Feng, CP | 1 |
| Artini, PG | 3 |
| Malacarne, E | 1 |
| Tomatis, V | 1 |
| Genazzani, AD | 8 |
| Zhao, H | 1 |
| Xing, C | 1 |
| Zhang, J | 1 |
| He, B | 1 |
| De Cicco, S | 1 |
| Immediata, V | 1 |
| Romualdi, D | 1 |
| Policola, C | 1 |
| Tropea, A | 1 |
| Di Florio, C | 1 |
| Tagliaferri, V | 1 |
| Scarinci, E | 1 |
| Della Casa, S | 1 |
| Lanzone, A | 2 |
| Apa, R | 1 |
| LE, TN | 1 |
| Wickham, EP | 1 |
| Nestler, JE | 5 |
| Tewari, S | 1 |
| Narula, SC | 1 |
| Singhal, SR | 1 |
| Sharma, RK | 1 |
| Nas, K | 1 |
| Tűű, L | 1 |
| Morgante, G | 5 |
| Massaro, MG | 3 |
| Di Sabatino, A | 4 |
| Cappelli, V | 4 |
| De Leo, V | 6 |
| Dinicola, S | 3 |
| Cucina, A | 2 |
| Morley, LC | 1 |
| Tang, T | 3 |
| Yasmin, E | 3 |
| Norman, RJ | 3 |
| Balen, AH | 3 |
| Stracquadanio, M | 2 |
| Ciotta, L | 2 |
| Palumbo, MA | 1 |
| Gateva, A | 2 |
| Kamenov, Z | 2 |
| Fraticelli, F | 1 |
| Celentano, C | 3 |
| Zecca, IA | 1 |
| Di Vieste, G | 2 |
| Liberati, M | 3 |
| Franzago, M | 1 |
| Di Nicola, M | 1 |
| Vitacolonna, E | 3 |
| Parthan, G | 1 |
| Bhansali, S | 1 |
| Kurpad, AV | 1 |
| Walia, R | 1 |
| Bhat, K | 1 |
| Bhansali, A | 1 |
| Miñambres, I | 1 |
| Cuixart, G | 1 |
| Gonçalves, A | 1 |
| Corcoy, R | 1 |
| Donnarumma, M | 1 |
| Marasca, C | 1 |
| Palma, M | 1 |
| Vastarella, M | 1 |
| Annunziata, MC | 1 |
| Fabbrocini, G | 1 |
| Garzon, S | 1 |
| Casarin, J | 1 |
| Franchi, M | 1 |
| Ghezzi, F | 1 |
| Ortiz-Flores, AE | 1 |
| Luque-Ramírez, M | 1 |
| Escobar-Morreale, HF | 1 |
| Fruzzetti, F | 3 |
| Canu, A | 1 |
| Formoso, G | 1 |
| Baldassarre, MPA | 1 |
| Ginestra, F | 1 |
| Carlucci, MA | 1 |
| Bucci, I | 1 |
| Consoli, A | 1 |
| Han, L | 1 |
| Xiao, Y | 1 |
| Pan, C | 1 |
| Li, Y | 1 |
| Ge, X | 1 |
| Yan, S | 1 |
| Wang, M | 1 |
| Fried, PJ | 1 |
| Pascual-Leone, A | 1 |
| Bolo, NR | 1 |
| Prati, A | 3 |
| Marchini, F | 1 |
| Petrillo, T | 1 |
| Napolitano, A | 1 |
| Simoncini, T | 3 |
| Fidecicchi, T | 1 |
| Palla, G | 1 |
| Gambacciani, M | 1 |
| Croze, ML | 3 |
| Soulage, CO | 3 |
| Musacchio, MC | 3 |
| Orvieto, R | 2 |
| Capasso, I | 1 |
| Esposito, E | 1 |
| Maurea, N | 1 |
| Montella, M | 1 |
| Crispo, A | 1 |
| De Laurentiis, M | 1 |
| D'Aiuto, M | 1 |
| Frasci, G | 1 |
| Botti, G | 1 |
| Grimaldi, M | 1 |
| Cavalcanti, E | 1 |
| Esposito, G | 1 |
| Fucito, A | 1 |
| Brillante, G | 1 |
| D'Aiuto, G | 1 |
| Ciliberto, G | 1 |
| Heimark, D | 1 |
| McAllister, J | 1 |
| Larner, J | 11 |
| Pizzo, A | 1 |
| Barbaro, L | 1 |
| Metges, CC | 1 |
| Görs, S | 1 |
| Lang, IS | 1 |
| Hammon, HM | 1 |
| Brüssow, KP | 1 |
| Weitzel, JM | 1 |
| Nürnberg, G | 1 |
| Rehfeldt, C | 1 |
| Otten, W | 1 |
| Do, HJ | 1 |
| Jin, T | 1 |
| Chung, JH | 1 |
| Hwang, JW | 1 |
| Shin, MJ | 1 |
| Santagni, S | 2 |
| Rattighieri, E | 2 |
| Chierchia, E | 2 |
| Despini, G | 1 |
| Marini, G | 1 |
| Porcaro, G | 1 |
| Li, XW | 1 |
| Hao, W | 1 |
| Liu, Y | 2 |
| Yang, JR | 1 |
| Costantino, D | 2 |
| Guaraldi, C | 2 |
| Chiu, TT | 3 |
| Carlomagno, G | 5 |
| Kim, JN | 1 |
| Han, SN | 1 |
| Kim, HK | 1 |
| Kolarov, G | 1 |
| Tosti, C | 1 |
| Cianci, EA | 1 |
| Formuso, C | 1 |
| Benvenga, S | 2 |
| Géloën, A | 1 |
| Bañuls, C | 2 |
| Rovira-Llopis, S | 2 |
| Falcón, R | 1 |
| Veses, S | 2 |
| Monzó, N | 1 |
| Víctor, VM | 2 |
| Rocha, M | 2 |
| Hernández-Mijares, A | 2 |
| Gao, Y | 1 |
| Zhang, M | 1 |
| Wu, T | 1 |
| Xu, M | 1 |
| Cai, H | 1 |
| Zhang, Z | 1 |
| Chang, HH | 1 |
| Chao, HN | 1 |
| Walker, CS | 1 |
| Choong, SY | 1 |
| Phillips, A | 1 |
| Loomes, KM | 1 |
| Facchinetti, F | 3 |
| Soulage, C | 1 |
| Di Renzo, GC | 1 |
| Hod, M | 1 |
| Cavalli, P | 1 |
| Kamenov, ZA | 1 |
| Gerli, S | 1 |
| Oliva, MM | 1 |
| Devroey, P | 1 |
| Matarrelli, B | 2 |
| Mattei, PA | 2 |
| Pavone, G | 2 |
| Paul, C | 1 |
| Maniglio, P | 1 |
| Triolo, O | 1 |
| Brady, DM | 1 |
| Harrath, AH | 1 |
| Alwasel, SH | 1 |
| Gao, YF | 1 |
| Zhang, MN | 1 |
| Wang, TX | 1 |
| Wu, TC | 1 |
| Ai, RD | 1 |
| Zhang, ZS | 1 |
| Ferrari, F | 1 |
| Ontiveros, AE | 1 |
| Roberts, RP | 1 |
| Saade, MM | 1 |
| Blackwell, SC | 1 |
| Sibai, BM | 1 |
| Refuerzo, JS | 1 |
| Longo, M | 1 |
| Milewska, EM | 1 |
| Czyzyk, A | 1 |
| Meczekalski, B | 1 |
| López-Doménech, S | 1 |
| Perini, D | 1 |
| Russo, M | 1 |
| Bucci, F | 1 |
| Gadducci, A | 1 |
| Legro, RS | 1 |
| Maurizi, AR | 1 |
| Menduni, M | 1 |
| Del Toro, R | 1 |
| Kyanvash, S | 1 |
| Maggi, D | 1 |
| Guglielmi, C | 1 |
| Pantano, AL | 1 |
| Defeudis, G | 1 |
| Fioriti, E | 1 |
| Manfrini, S | 1 |
| Pozzilli, P | 1 |
| Antony, PJ | 1 |
| Gandhi, GR | 1 |
| Stalin, A | 1 |
| Balakrishna, K | 1 |
| Toppo, E | 1 |
| Sivasankaran, K | 1 |
| Ignacimuthu, S | 1 |
| Al-Dhabi, NA | 1 |
| Villeneuve, MC | 1 |
| Ostlund, RE | 3 |
| Baillargeon, JP | 3 |
| Papaleo, E | 2 |
| Lord, JM | 2 |
| Giordano, D | 3 |
| Santamaria, A | 3 |
| Quattrone, S | 1 |
| Galazis, N | 1 |
| Galazi, M | 1 |
| Atiomo, W | 1 |
| Koldobskiy, MA | 1 |
| Bello, NT | 1 |
| Maxwell, M | 1 |
| Potter, JJ | 1 |
| Juluri, KR | 1 |
| Maag, D | 1 |
| Kim, S | 1 |
| Huang, AS | 1 |
| Dailey, MJ | 1 |
| Saleh, M | 1 |
| Snowman, AM | 1 |
| Moran, TH | 1 |
| Mezey, E | 1 |
| Snyder, SH | 1 |
| Minozzi, M | 1 |
| Rizzo, P | 1 |
| Raffone, E | 1 |
| Fujitaka, K | 1 |
| Otani, H | 1 |
| Jo, F | 1 |
| Jo, H | 1 |
| Nomura, E | 1 |
| Iwasaki, M | 1 |
| Nishikawa, M | 1 |
| Iwasaka, T | 1 |
| Cittadini, E | 1 |
| Kim, BH | 1 |
| Park, JY | 1 |
| Jang, JB | 1 |
| Moon, DC | 1 |
| Kim, HJ | 1 |
| Park, KS | 1 |
| Lee, SK | 1 |
| Min, KW | 1 |
| Han, KA | 1 |
| Kim, YK | 1 |
| Ku, BJ | 1 |
| Interdonato, ML | 1 |
| Vieste, GD | 1 |
| Benedetto, AD | 1 |
| Donà, G | 1 |
| Sabbadin, C | 1 |
| Fiore, C | 1 |
| Bragadin, M | 1 |
| Giorgino, FL | 1 |
| Ragazzi, E | 1 |
| Clari, G | 1 |
| Bordin, L | 1 |
| Armanini, D | 1 |
| Dante, G | 1 |
| Shen, H | 1 |
| Shao, M | 1 |
| Cho, KW | 1 |
| Wang, S | 1 |
| Chen, Z | 1 |
| Sheng, L | 1 |
| Wang, T | 1 |
| Rui, L | 1 |
| Kedikova, S | 1 |
| Sirakov, M | 1 |
| Boyadzhieva, M | 1 |
| Ricchieri, F | 1 |
| Campedelli, A | 1 |
| Vella, RE | 1 |
| Pillon, NJ | 1 |
| Soula, HA | 1 |
| Hadji, L | 1 |
| Guichardant, M | 1 |
| D'Angelo, M | 1 |
| Di Berardino, OM | 1 |
| Papini, F | 1 |
| Simi, G | 1 |
| Ruggiero, M | 1 |
| Cela, V | 1 |
| Iijima, T | 1 |
| Kitaoka, H | 2 |
| Yamada, K | 1 |
| Kawamori, R | 1 |
| Kadowaki, T | 1 |
| Ishida, H | 1 |
| Jung, TS | 1 |
| Hahm, JR | 1 |
| Kim, JJ | 1 |
| Jung, JH | 1 |
| Kang, MY | 1 |
| Moon, SW | 1 |
| Lee, KW | 1 |
| Kim, HC | 1 |
| Lee, JD | 1 |
| Kim, JH | 1 |
| Kim, DR | 1 |
| Chung, SI | 1 |
| Diamanti-Kandarakis, E | 1 |
| Apridonidze, T | 1 |
| Iuorno, MJ | 2 |
| Aso, Y | 1 |
| Yamamoto, R | 1 |
| Suetsugu, M | 1 |
| Matsumoto, S | 1 |
| Wakabayashi, S | 1 |
| Matsutomo, R | 1 |
| Takebayashi, K | 1 |
| Inukai, T | 1 |
| Proctor, SD | 1 |
| Kelly, SE | 1 |
| Vine, DF | 1 |
| Russell, JC | 1 |
| Abe, M | 1 |
| Kikuchi, F | 1 |
| Kaizu, K | 1 |
| Matsumoto, K | 2 |
| Dayhaw-Barker, P | 1 |
| Galasko, GT | 1 |
| Bao, Y | 1 |
| Broomfield, SJ | 1 |
| Hooper, NM | 1 |
| Turner, AJ | 1 |
| Suzuki, S | 1 |
| Kawasaki, H | 1 |
| Satoh, Y | 1 |
| Ohtomo, M | 1 |
| Hirai, M | 1 |
| Hirai, A | 1 |
| Hirai, S | 1 |
| Onoda, M | 1 |
| Matsumoto, M | 1 |
| Hinokio, Y | 1 |
| Asplin, I | 1 |
| Galasko, G | 1 |
| Ortmeyer, HK | 5 |
| Bodkin, NL | 1 |
| Lilley, K | 1 |
| Hansen, BC | 4 |
| Huang, LC | 2 |
| Zhang, L | 1 |
| Fonteles, MC | 1 |
| Houston, DB | 1 |
| Zhang, C | 1 |
| Craig, JW | 1 |
| Sakamoto, N | 1 |
| Uno, T | 1 |
| Ishii, J | 1 |
| Inoue, I | 1 |
| Iwamoto, Y | 1 |
| Yano, M | 1 |
| Miyake, S | 1 |
| Ueki, Y | 1 |
| Yamaguchi, Y | 1 |
| Akazawa, S | 1 |
| Tominaga, Y | 1 |
| Yoshioka, K | 1 |
| Yokoo, S | 1 |
| Yoshida, T | 1 |
| Yoshino, K | 2 |
| Takeda, N | 2 |
| Sugimoto, M | 2 |
| Nakashima, K | 2 |
| Okumura, S | 2 |
| Hattori, J | 2 |
| Sasaki, A | 1 |
| Kawachi, S | 1 |
| Takami, K | 1 |
| Takami, R | 1 |
| Yasuda, K | 2 |
| Davis, A | 1 |
| Christiansen, M | 1 |
| Horowitz, JF | 1 |
| Klein, S | 1 |
| Hellerstein, MK | 1 |
| Jakubowicz, DJ | 1 |
| Ishimori, M | 1 |
| Kennington, AS | 1 |
| Hill, CR | 1 |
| Craig, J | 1 |
| Bogardus, C | 1 |
| Raz, I | 1 |
| Romero, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Inositols on Insulin Resistance in Children With Obesity (ONIRICO Trial)[NCT05701813] | 56 participants (Anticipated) | Interventional | 2023-02-01 | Not yet recruiting | |||
| Effect of Myoinositol on Serum Asprosin Levels in Pregnant Women[NCT05943158] | 40 participants (Actual) | Interventional | 2021-06-01 | Completed | |||
| Myoinositol Supplementation, Insulin Resistance and Fetal Sonographic Parameters in Gestational Diabetes, Diet Treated: a Prospective, Randomized, Placebo-controlled Study[NCT03763669] | 120 participants (Actual) | Interventional | 2018-11-14 | Completed | |||
| Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS:A Double Blind Randomized Placebo Controlled Trial[NCT05653895] | 250 participants (Anticipated) | Interventional | 2022-12-07 | Recruiting | |||
| The Effects of Acetyl L--Carnitine and Myo/Chiro-Inositol on Improving Ovulation, Pregnancy Rate, Ovarian Function and Perceived Stress Response in Patients With PCOS[NCT05767515] | 120 participants (Anticipated) | Interventional | 2023-04-15 | Not yet recruiting | |||
| Different Effects of Inositol Stereoisomers on Insulin Sensitivity in Women With Gestational Diabetes[NCT02097069] | 80 participants (Anticipated) | Interventional | 2014-04-30 | Not yet recruiting | |||
| A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy[NCT02097342] | Phase 4 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Recruiting | ||
| Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial[NCT04273256] | Phase 2/Phase 3 | 226 participants (Anticipated) | Interventional | 2020-02-11 | Recruiting | ||
| Effects of a Supplementation With Zinc and Myo-inositol in Paediatric Obesity[NCT03283813] | Phase 4 | 60 participants (Anticipated) | Interventional | 2018-02-05 | Recruiting | ||
| Reduction of Insulin Therapy Under Myo-inositol for the Treatment of Gestational Diabetes Mellitus: a Randomized Multicenter and Prospective Trial. MYO-GDM Study[NCT03875755] | 1,080 participants (Anticipated) | Interventional | 2020-03-04 | Recruiting | |||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| Treatment of Functional Ovarian Cyst Randomised Clinical Trial[NCT05244811] | Phase 3 | 60 participants (Anticipated) | Interventional | 2022-02-20 | Not yet recruiting | ||
| A Pilot Study of D-Chiro-Inositol Plus Folic Acid in Overweight Patients With Type 1 Diabetes[NCT02730949] | Phase 3 | 26 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| The Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve Parameters in Subfertile Women[NCT01290432] | 15 participants (Actual) | Interventional | 2011-02-28 | Completed | |||
| Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients.[NCT01246310] | 24 participants (Actual) | Interventional | 2010-11-30 | Terminated (stopped due to The number of patients enrolled was insufficient to match the calculated sample size and to carry out statistical analyses) | |||
| Improving Oocyte Retrieval Using a Combined Therapy of Recombinant Follicle Stimulating Hormone (rFSH) and Inositol and Melatonin[NCT01267604] | Phase 4 | 0 participants (Actual) | Interventional | 2010-12-31 | Withdrawn | ||
| A Prospective, Randomized, Double Blind, Study on the Clinical Efficacy Myo-inositol Versus D-chiro-inositol in Women Undergoing in Vitro Fertilization Embryo Transfer.[NCT01338844] | Phase 4 | 0 participants | Interventional | Completed | |||
| [NCT01511835] | Phase 4 | 0 participants | Interventional | Recruiting | |||
| Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial[NCT02523898] | Phase 2 | 388 participants (Anticipated) | Interventional | 2015-11-30 | Enrolling by invitation | ||
| Effects of Myo-inositol Plus Melatonin in Perimenopausal Women[NCT01325389] | 0 participants | Interventional | Recruiting | ||||
| Improved Maternal and Fetal Outcomes Associated With Inositol Dietary Supplementation in Women With Early Gestational Diabetes Mellitus[NCT01342874] | 30 participants (Actual) | Observational | 2010-08-31 | Completed | |||
| [NCT01511822] | Phase 4 | 0 participants | Interventional | Completed | |||
| Effects of Different Doses of Pinitol on Carbohydrate Metabolism Parameters in Healthy Subjects: a Randomized Cross-over Placebo-controlled Study[NCT01738763] | 30 participants (Actual) | Interventional | 2011-07-31 | Completed | |||
| Graceful Lifestyle Changes Intervention Study for Women With PCOS and Infertility[NCT02630485] | 240 participants (Anticipated) | Interventional | 2015-12-31 | Not yet recruiting | |||
| [NCT01514942] | Phase 4 | 0 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
45 reviews available for inositol and Insulin Resistance
| Article | Year |
|---|---|
Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial.
Topics: Female; Folic Acid; Humans; Inositol; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndr | 2022 |
Positive Effects of α-Lactalbumin in the Management of Symptoms of Polycystic Ovary Syndrome.
Topics: Dysbiosis; Female; Humans; Inositol; Insulin Resistance; Lactalbumin; Polycystic Ovary Syndrome; Pre | 2022 |
Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Dietary Supplements; Female; Humans; Hypert | 2023 |
The Role of Inositols in the Hyperandrogenic Phenotypes of PCOS: A Re-Reading of Larner's Results.
Topics: Androgens; Aromatase; Estrogens; Female; Follicle Stimulating Hormone; Humans; Hyperandrogenism; Ino | 2023 |
The "Asthma-Polycystic Ovary Overlap Syndrome" and the Therapeutic Role of Myo-Inositol.
Topics: Asthma; Female; Humans; Inositol; Insulin Resistance; Polycystic Ovary Syndrome | 2023 |
Alpha Lipoic Acid Efficacy in PCOS Treatment: What Is the Truth?
Topics: Antioxidants; Diabetes Mellitus, Type 2; Female; Humans; Inositol; Insulin; Insulin Resistance; Metf | 2023 |
Myoinositol in the Prevention of Gestational Diabetes Mellitus: Is It Sensible?
Topics: Animals; Biomarkers; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Humans; Hypo | 2019 |
Current treatment for polycystic ovary syndrome: focus on adolescence.
Topics: Adolescent; Contraceptives, Oral, Hormonal; Female; Gene-Environment Interaction; Humans; Hypoglycem | 2020 |
Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation.
Topics: Animals; Cholesterol; Dietary Supplements; Female; Glutathione Peroxidase; Humans; Inositol; Insulin | 2020 |
The use of D-chiro-Inositol in clinical practice.
Topics: Aromatase; Down-Regulation; Female; Humans; Inositol; Insulin; Insulin Resistance; Male; Polycystic | 2021 |
Natural Molecules in the Management of Polycystic Ovary Syndrome (PCOS): An Analytical Review.
Topics: Ascorbic Acid; Dietary Supplements; Dyslipidemias; Fatty Acids, Omega-3; Female; Flavanones; Flavono | 2021 |
Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
Topics: Berberine; Clinical Decision-Making; Female; Humans; Hypoglycemic Agents; Inositol; Insulin; Insulin | 2021 |
Insulin sensitizers in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Adult; Age Factors; Contraceptives, Oral, Hormonal; Female; Humans; Hypoglycemic Agents; | 2017 |
Therapeutic approach for metabolic disorders and infertility in women with PCOS.
Topics: Androgen Antagonists; Anovulation; Clomiphene; Contraceptives, Oral, Hormonal; Female; Gonadotropins | 2018 |
Modulation of both Insulin Resistance and Cancer Growth by Inositol.
Topics: Animals; Blood Glucose; Growth Inhibitors; Humans; Inositol; Insulin Resistance; Neoplasms; Tumor Bu | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review.
Topics: Diabetes, Gestational; Female; Humans; Inositol; Insulin Resistance; Polycystic Ovary Syndrome; Preg | 2018 |
Effects of inositol on glucose homeostasis: Systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Homeostasis; Humans; Inositol; Insulin Resi | 2019 |
Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.
Topics: Female; Fertility; Humans; Inositol; Insulin Resistance; Polycystic Ovary Syndrome | 2018 |
Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes.
Topics: Animals; Diabetes Mellitus; Female; Glucose Intolerance; Humans; Inositol; Insulin; Insulin Resistan | 2018 |
Inositol and antioxidant supplementation: Safety and efficacy in pregnancy.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Humans; In | 2019 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Topics: Animals; Blood Glucose; Cataract; Diabetes, Gestational; Diabetic Nephropathies; Diet; Female; Human | 2013 |
Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
Topics: Animals; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Inositol; Insulin Resis | 2014 |
The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
Topics: Androgens; Animals; Drug Therapy, Combination; Female; Humans; Inositol; Insulin Resistance; Oocytes | 2014 |
Myo-Inositol Supplementation to Prevent Gestational Diabetes Mellitus.
Topics: Animals; Diabetes, Gestational; Dietary Supplements; Female; Humans; Incidence; Inositol; Insulin Re | 2016 |
Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Inositol; Insulin Resistance; Metabolic Syndrome; Polycys | 2016 |
Physiological role and clinical utility of inositols in polycystic ovary syndrome.
Topics: Female; Humans; Hyperinsulinism; Inositol; Insulin Resistance; Polycystic Ovary Syndrome; Stereoisom | 2016 |
Inositol and human reproduction. From cellular metabolism to clinical use.
Topics: Female; Humans; Inositol; Insulin Resistance; Ovulation; Polycystic Ovary Syndrome; Reproductive Tec | 2016 |
Inositol as putative integrative treatment for PCOS.
Topics: Female; Humans; Hyperandrogenism; Hyperinsulinism; Inositol; Inositol Phosphates; Insulin; Insulin R | 2016 |
Ovulation induction in polycystic ovary syndrome: Current options.
Topics: Anovulation; Anti-Obesity Agents; Aromatase Inhibitors; Bariatric Surgery; Clomiphene; Diet Therapy; | 2016 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Contribution of myo-inositol to reproduction.
Topics: Animals; Female; Fertility; Humans; Inositol; Insulin Resistance; Oogenesis; Polycystic Ovary Syndro | 2009 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Live Bir | 2010 |
D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.
Topics: Female; Humans; Inositol; Insulin Resistance; Ovulation; Polycystic Ovary Syndrome | 2011 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Topics: Adult; Dietary Supplements; Female; Fertility Agents, Female; Folic Acid; Gonadotropins, Pituitary; | 2012 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Female; Inositol; Insulin | 2012 |
[Sulfonylurea and alpha-glucosidase inhibitor].
Topics: Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Gl | 2002 |
[Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
Topics: Acarbose; Animals; Biguanides; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug T | 2002 |
[Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
Topics: Acarbose; Cyclohexanes; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Enzyme | 2003 |
Mechanisms of pathogenesis in diabetes mellitus.
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Histocompatibilit | 1995 |
[Oral hypoglycemic agents--overview].
Topics: Acarbose; Administration, Oral; Biguanides; Chromans; Glycoside Hydrolase Inhibitors; Humans; Hypogl | 1997 |
[Measures to meet the side effects of the orally administered antihyperglycemic drugs].
Topics: Acarbose; Administration, Oral; Animals; Biguanides; Cardiovascular System; Chromans; Drug Interacti | 1997 |
[Alpha-glucosidase inhibitor and insulin sensitizer combination therapy in NIDDM].
Topics: Acarbose; Animals; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hydrola | 1997 |
[Management of postprandial hyperglycemia].
Topics: Acarbose; Diabetes Mellitus, Type 2; Diet, Diabetic; Exercise Therapy; Humans; Hyperglycemia; Hypogl | 1997 |
Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome.
Topics: Androgens; Female; Humans; Inositol; Inositol Phosphates; Insulin; Insulin Resistance; Oligosacchari | 2000 |
D-chiro-inositol in insulin action and insulin resistance-old-fashioned biochemistry still at work.
Topics: Animals; Diabetes Mellitus, Type 2; GTP-Binding Proteins; Humans; Inositol; Inositol Phosphates; Ins | 2001 |
36 trials available for inositol and Insulin Resistance
| Article | Year |
|---|---|
Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study.
Topics: Female; Humans; Inositol; Insulin Resistance; Luteinizing Hormone; Menstrual Cycle; Polycystic Ovary | 2022 |
The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial.
Topics: Adiponectin; Adult; Blood Glucose; Body Composition; Body Mass Index; Female; Gonadal Steroid Hormon | 2022 |
Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind pilot trial with nested qualitative study.
Topics: Diabetes, Gestational; Double-Blind Method; Female; Humans; Inositol; Insulin Resistance; Male; Pilo | 2022 |
The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial.
Topics: Diabetes, Gestational; Dietary Supplements; Female; Folic Acid; Humans; Inositol; Insulin Resistance | 2023 |
A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Inositol; Insulin; Insulin Resistance; Metformin; Polycystic Ov | 2023 |
Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: study protocol for a randomized controlled trial.
Topics: Diabetes, Gestational; Dietary Supplements; Female; Glucose Tolerance Test; Glycated Hemoglobin; Gre | 2020 |
Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study.
Topics: Adult; Birth Weight; Case-Control Studies; Diabetes, Gestational; Dietary Supplements; Female; Folic | 2021 |
Effect of Non-Surgical Periodontal Therapy Along With Myo-Inositol on High-Sensitivity C-Reactive Protein and Insulin Resistance in Women With Polycystic Ovary Syndrome and Chronic Periodontitis: A Randomized Controlled Trial.
Topics: Adolescent; Adult; Anthropometry; C-Reactive Protein; Chronic Periodontitis; Demography; Dental Scal | 2017 |
Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial.
Topics: Adolescent; Adult; Diabetes, Gestational; Dose-Response Relationship, Drug; Female; Humans; Inositol | 2018 |
Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; H | 2018 |
Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial.
Topics: Aged; Biomarkers; Blood Glucose; Body Mass Index; Breast Neoplasms; Caloric Restriction; Cholesterol | 2013 |
[Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
Topics: Adult; Antioxidants; Blood Glucose; Body Mass Index; Drug Therapy, Combination; Electron Transport; | 2013 |
Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
Topics: Adolescent; Adult; Amenorrhea; Dietary Supplements; Double-Blind Method; Female; Folic Acid; Follicl | 2014 |
Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.
Topics: Adult; Body Mass Index; Dietary Supplements; Family Health; Female; Gonadotropin-Releasing Hormone; | 2014 |
Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Infant, Newborn; Infertility, Female; I | 2015 |
[Combination inositol and glucomannan in PCOS patients].
Topics: Adult; Blood Glucose; Drug Therapy, Combination; Female; Humans; Inositol; Insulin; Insulin Resistan | 2014 |
Myo-inositol vs. D-chiro inositol in PCOS treatment.
Topics: Acne Vulgaris; Adult; Double-Blind Method; Female; Hirsutism; Humans; Inositol; Insulin Resistance; | 2015 |
Chronic consumption of an inositol-enriched carob extract improves postprandial glycaemia and insulin sensitivity in healthy subjects: A randomized controlled trial.
Topics: Adult; Blood Glucose; Dietary Supplements; Double-Blind Method; Fabaceae; Female; Fruit; Humans; Hyp | 2016 |
Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Topics: Adult; Antioxidants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Fem | 2015 |
Effect of consumption of a carob pod inositol-enriched beverage on insulin sensitivity and inflammation in middle-aged prediabetic subjects.
Topics: Adult; Aged; Beverages; Double-Blind Method; Female; Galactans; Glycated Hemoglobin; Humans; Inflamm | 2016 |
Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Metformin; Out | 2017 |
A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes.
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Female; Folic Acid; Humans; Inositol; I | 2017 |
Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Female; Humans; Inositol; Insulin; Insulin Resistanc | 2011 |
Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Female; Humans; Inositol; Insulin; Insulin Resistanc | 2011 |
Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Female; Humans; Inositol; Insulin; Insulin Resistanc | 2011 |
Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Female; Humans; Inositol; Insulin; Insulin Resistanc | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes.
Topics: Adiponectin; Adult; Blood Glucose; Diabetes, Gestational; Dietary Supplements; Female; Glucose Toler | 2011 |
The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome.
Topics: Adult; Androstenedione; Cholesterol; Cholesterol, LDL; Contraceptives, Oral, Combined; Female; Human | 2011 |
Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome.
Topics: Adiponectin; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; | 2011 |
Effects of pinitol on glycemic control, insulin resistance and adipocytokine levels in patients with type 2 diabetes mellitus.
Topics: Adipokines; Adiponectin; Adult; Aged; Blood Glucose; C-Peptide; C-Reactive Protein; Diabetes Mellitu | 2012 |
One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Caloric Restriction; Cholesterol, HDL; Dietary Suppl | 2012 |
Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Down-Regulation; Drug Administration Schedule; Erythrocyte Count; Erythrocytes | 2012 |
Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
Topics: Adult; Body Mass Index; Dietary Supplements; Female; Folic Acid; Follicle Stimulating Hormone; Gluco | 2012 |
Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial.
Topics: Adult; Case-Control Studies; Diabetes, Gestational; Dietary Supplements; Double-Blind Method; Female | 2013 |
Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Drug Therapy, Combination; Estradiol; Female; Folic Acid; | 2013 |
Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent | 2007 |
Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis.
Topics: Aged; Asian People; Blood Glucose; Case-Control Studies; Demography; Diabetes Mellitus, Type 2; Drug | 2007 |
Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients.
Topics: Blood Glucose; Cholesterol; Cholesterol, HDL; Data Interpretation, Statistical; Diabetes Mellitus, T | 1998 |
Effect of pinitol treatment on insulin action in subjects with insulin resistance.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Cl | 2000 |
77 other studies available for inositol and Insulin Resistance
| Article | Year |
|---|---|
Effects of a pinitol-rich
Topics: Adipocytes; Animals; Glycyrrhiza; Humans; Hypertrophy; Inflammation; Inositol; Insulin; Insulin Resi | 2022 |
Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes.
Topics: Diabetes, Gestational; Female; Humans; Inositol; Insulin; Insulin Resistance; Polycystic Ovary Syndr | 2022 |
Does Alpha-lipoic acid improve effects on polycystic ovary syndrome?
Topics: Female; Humans; Inositol; Insulin; Insulin Resistance; Polycystic Ovary Syndrome; Thioctic Acid | 2022 |
Dietary administration of D-chiro-inositol attenuates sex-specific metabolic imbalances in the 5xFAD mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Female; Humans; Inositol; Insulin; Insulin Resis | 2022 |
D-Chiro-inositol in PCOS: the myths and what we know about the reality.
Topics: Female; Humans; Inositol; Insulin Resistance; Polycystic Ovary Syndrome | 2022 |
Differences in levothyroxine action on thyroid autoimmunity and hypothalamic-pituitary-thyroid axis activity between metformin- and myo-inositol-treated women with autoimmune subclinical hypothyroidism.
Topics: Autoimmunity; C-Reactive Protein; Female; Glucose; Hashimoto Disease; Humans; Hypothyroidism; Inosit | 2022 |
The impact of vitamin D on thyroid autoimmunity and hypothalamic-pituitary-thyroid axis activity in myo-inositol-treated and myo-inositol-naïve women with autoimmune thyroiditis: A pilot study.
Topics: Autoimmunity; Female; Glucose; Hashimoto Disease; Humans; Inositol; Insulin Resistance; Iodide Perox | 2022 |
Effects of nutrition on metabolic and endocrine outcomes in women with polycystic ovary syndrome: an umbrella review of meta-analyses of randomized controlled trials.
Topics: Blood Glucose; Curcumin; Female; Fish Oils; Humans; Inositol; Insulin; Insulin Resistance; Polycysti | 2023 |
Myo-Inositol Enhances the Inhibitory Effect of Metformin on Gonadotropin Levels in Postmenopausal Women.
Topics: Female; Follicle Stimulating Hormone; Glycated Hemoglobin; Gonadotropins; Humans; Inositol; Insulin; | 2022 |
Myo-Inositol Enhances the Inhibitory Effect of Metformin on Gonadotropin Levels in Postmenopausal Women.
Topics: Female; Follicle Stimulating Hormone; Glycated Hemoglobin; Gonadotropins; Humans; Inositol; Insulin; | 2022 |
Myo-Inositol Enhances the Inhibitory Effect of Metformin on Gonadotropin Levels in Postmenopausal Women.
Topics: Female; Follicle Stimulating Hormone; Glycated Hemoglobin; Gonadotropins; Humans; Inositol; Insulin; | 2022 |
Myo-Inositol Enhances the Inhibitory Effect of Metformin on Gonadotropin Levels in Postmenopausal Women.
Topics: Female; Follicle Stimulating Hormone; Glycated Hemoglobin; Gonadotropins; Humans; Inositol; Insulin; | 2022 |
Myo-Inositol Potentiates the Inhibitory Effect of Metformin on Prolactin Levels.
Topics: Adrenocorticotropic Hormone; Blood Glucose; Female; Glycated Hemoglobin; Humans; Hyperprolactinemia; | 2023 |
The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling.
Topics: Animals; Diet; Diphosphates; Hyperglycemia; Inositol; Insulin; Insulin Resistance; Lipid Metabolism; | 2023 |
The effects of myo-inositol and probiotic supplementation in a high-fat-fed preclinical model of glucose intolerance in pregnancy.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes, Gestational; Diet, High-Fat; Dietary Supplements; | 2020 |
The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment.
Topics: Adult; AMP-Activated Protein Kinases; Cells, Cultured; Endometrium; Enzyme Activation; Female; Gluco | 2020 |
Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model.
Topics: Animals; Blood Glucose; Body Weight; Estrous Cycle; Female; Follicle Stimulating Hormone; Gene Expre | 2020 |
Myo-inositol oxygenese activity in second trimester of pregnancy: altered myoinositol catabolism in gestational diabetes mellitus.
Topics: Blood Glucose; Diabetes, Gestational; Female; Humans; Inositol; Inositol Oxygenase; Insulin; Insulin | 2022 |
Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study.
Topics: Adolescent; Adult; Blood Glucose; Contraceptives, Oral, Combined; Female; Glycated Hemoglobin; Human | 2020 |
Direct Effects of D-Chiro-Inositol on Insulin Signaling and Glucagon Secretion of Pancreatic Alpha Cells.
Topics: Animals; Cell Line, Tumor; Glucagon; Glucagon-Secreting Cells; Inositol; Insulin; Insulin Resistance | 2020 |
Inositols: reflections on how to choose the appropriate one for PCOS.
Topics: Female; Humans; Inositol; Insulin Resistance; Metabolic Syndrome; Polycystic Ovary Syndrome; Vitamin | 2020 |
Letter to "May myo-inositol and D-chiro-inositol (40:1) treatment be a good option on normal-weighted polycystic ovary syndrome patients without insulin resistance?"
Topics: Body Weight; Female; Humans; Inositol; Insulin Resistance; Polycystic Ovary Syndrome | 2021 |
Sex-Specific Effects of Myo-Inositol Ingested During Lactation in the Improvement of Metabolic Health in Adult Rats.
Topics: Adipose Tissue, White; Animals; Body Weight; Caloric Restriction; Dietary Supplements; Eating; Energ | 2021 |
Activation of PI3K/Akt Signaling Pathway in Rat Hypothalamus Induced by an Acute Oral Administration of D-Pinitol.
Topics: Administration, Oral; Animals; Blood Glucose; Enzyme Activation; Glucagon; Homeostasis; Hypothalamus | 2021 |
Differential Gene Expression and Biological Analyses of Primary Hepatocytes Following D-Chiro-Inositol Supplement.
Topics: Animals; Biomarkers; Dietary Supplements; Enzyme Inhibitors; Gene Expression Regulation; Gluconeogen | 2021 |
The relevance of inositols treatment for PCOS before and during ART.
Topics: Female; Humans; Inositol; Insulin Resistance; Polycystic Ovary Syndrome; Proto-Oncogene Proteins c-a | 2021 |
Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action.
Topics: Adolescent; Adult; Androstenedione; Body Mass Index; Dehydroepiandrosterone Sulfate; Drug Therapy, C | 2017 |
A comparative study between myo-inositol and metformin in the treatment of insulin-resistant women.
Topics: Adult; Body Mass Index; Fasting; Female; Folic Acid; Humans; Inositol; Insulin; Insulin Resistance; | 2017 |
Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients.
Topics: Adult; Blood Glucose; Body Mass Index; Body Weight; Drug Therapy, Combination; Female; Humans; Hyper | 2018 |
An oral supplementation based on myo-inositol, folic acid and liposomal magnesium may act synergistically with antibiotic therapy and can improve metabolic profile in patients affected by Hidradenitis suppurativa: our experience.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Bacterial Agents; Clindamycin; Dietary Supplem | 2020 |
Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Body Weight; Drug Therapy, Combination; Estradiol; Female; Folli | 2019 |
d- chiro-Inositol Ameliorates High Fat Diet-Induced Hepatic Steatosis and Insulin Resistance via PKCε-PI3K/AKT Pathway.
Topics: Animals; Diet, High-Fat; Fatty Liver; Hep G2 Cells; Hepatocytes; Humans; Hypoglycemic Agents; Inosit | 2019 |
Diabetes and the link between neuroplasticity and glutamate in the aging human motor cortex.
Topics: Aged; Aged, 80 and over; Aging; Aspartic Acid; Creatine; Diabetes Mellitus, Type 2; Female; Glucose; | 2019 |
Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
Topics: Adult; Androstenedione; Drug Therapy, Combination; Estradiol; Female; Follicle Stimulating Hormone; | 2019 |
Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Female; Hirsutism; Humans; Inositol; Insulin Resistance; Organ Size; Ovary; | 2020 |
Alterations in thyroid function among the different polycystic ovary syndrome phenotypes.
Topics: Adult; Body Mass Index; Drug Therapy, Combination; Female; Hospitals, University; Humans; Hypoglycem | 2013 |
Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls.
Topics: Adult; Carbohydrate Epimerases; Female; Humans; Inositol; Insulin Resistance; Polycystic Ovary Syndr | 2014 |
Low and high dietary protein:carbohydrate ratios during pregnancy affect materno-fetal glucose metabolism in pigs.
Topics: Adaptation, Physiological; Animals; Area Under Curve; Blood Glucose; Brain; Diet; Diet, Carbohydrate | 2014 |
Voglibose administration regulates body weight and energy intake in high fat-induced obese mice.
Topics: Adiposity; Agouti-Related Protein; Animals; Appetite; Body Weight; Diet, High-Fat; Energy Intake; Ge | 2014 |
[Effect of sequoyitol on expression of NOX4 and eNOS in aortas of type 2 diabetic rats].
Topics: Animals; Aorta; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2014 |
[Role of D-chiro-inositol in glucidic metabolism alterations during pregnancy].
Topics: Adult; Blood Glucose; Diabetes, Gestational; Female; Humans; Hunger; Hypoglycemia; Hypoglycemic Agen | 2014 |
Phytic acid and myo-inositol support adipocyte differentiation and improve insulin sensitivity in 3T3-L1 cells.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Blood Glucose; Cell Differentiation; Glucose Transporter Type 4; | 2014 |
Myo-inositol: with or without.
Topics: Carbohydrate Epimerases; Female; Humans; Inositol; Insulin Resistance; Polycystic Ovary Syndrome | 2015 |
Abnormalities in myo-inositol metabolism associated with type 2 diabetes in mice fed a high-fat diet: benefits of a dietary myo-inositol supplementation.
Topics: Adipokines; Adipose Tissue, White; Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Dietary Suppl | 2015 |
Effects of D-Pinitol on Insulin Resistance through the PI3K/Akt Signaling Pathway in Type 2 Diabetes Mellitus Rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Fabaceae; Glucose Tolerance Test; Glycogen Syntha | 2015 |
Renal depletion of myo-inositol is associated with its increased degradation in animal models of metabolic disease.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypertension; Inositol; Inositol O | 2015 |
Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS.
Topics: Congenital Abnormalities; Diabetes, Gestational; Female; Humans; Inositol; Insulin Resistance; Metab | 2015 |
Does myo-inositol effect on PCOS follicles involve cytoskeleton regulation?
Topics: Amenorrhea; Animals; Cadherins; Corpus Luteum; Cytoskeleton; Epithelial-Mesenchymal Transition; Fema | 2016 |
Hypoglycemic effect of D-chiro-inositol in type 2 diabetes mellitus rats through the PI3K/Akt signaling pathway.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose Transpor | 2016 |
The effect of combined inositol supplementation on maternal metabolic profile in pregnancies complicated by metabolic syndrome and obesity.
Topics: Animals; Biomarkers; Blood Glucose; Dietary Supplements; Disease Models, Animal; Female; Gastric Inh | 2016 |
Myoinositol ameliorates high-fat diet and streptozotocin-induced diabetes in rats through promoting insulin receptor signaling.
Topics: Administration, Oral; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diet, Hi | 2017 |
Hyperinsulinemia is closely related to low urinary clearance of D-chiro-inositol in men with a wide range of insulin sensitivity.
Topics: 17-alpha-Hydroxypregnenolone; Adolescent; Adult; Androstenedione; Blood Glucose; Cross-Sectional Stu | 2009 |
Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain.
Topics: Adipogenesis; Aging; Animals; Cell Culture Techniques; Diet; Diphosphates; Inositol; Inositol Phosph | 2010 |
The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen.
Topics: Adult; Case-Control Studies; Chi-Square Distribution; Dietary Supplements; Female; Fertility Agents, | 2011 |
Inositol effects on ovulation induction in patients with polycystic ovary syndrome.
Topics: Dietary Supplements; Female; Fertility Agents, Female; Gonadotropins; Humans; Infertility, Female; I | 2011 |
Comments on the role of inositol supplementation in patients with polycystic ovary syndrome.
Topics: Dietary Supplements; Female; Fertility Agents, Female; Gonadotropins; Humans; Infertility, Female; I | 2011 |
The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen.
Topics: Dietary Supplements; Female; Fertility Agents, Female; Gonadotropins; Humans; Infertility, Female; I | 2011 |
LC-MS/MS method for the quantification of myo- and chiro-inositol as the urinary biomarkers of insulin resistance in human urine.
Topics: Biomarkers; Chromatography, Liquid; Humans; Inositol; Insulin Resistance; Sensitivity and Specificit | 2012 |
Herbal constituent sequoyitol improves hyperglycemia and glucose intolerance by targeting hepatocytes, adipocytes, and β-cells.
Topics: Adipocytes, White; Animals; Cell Line; Cells, Cultured; Diabetes Mellitus, Experimental; Female; Glu | 2012 |
[Myoinositol--alternative treatment of insulin resistance in adolescents].
Topics: Adolescent; Female; Humans; Inositol; Inositol Phosphates; Insulin; Insulin Resistance; Polycystic O | 2011 |
Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice.
Topics: Adipocytes; Adipose Tissue, White; Administration, Oral; Animals; Female; Glucose Tolerance Test; In | 2013 |
[Achieving better control of blood sugar--understanding of oral hypoglycemic agents according to their characteristics in pharmacological action mechanism (discussion)].
Topics: Administration, Oral; Cardiovascular Diseases; Cyclohexanes; Diabetes Complications; Diabetes Mellit | 2004 |
Determination of urinary Myo-/chiro-inositol ratios from Korean diabetes patients.
Topics: Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Inositol; Insulin | 2005 |
Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Analysis of Variance; Blood Pressure; Body Mass Index; Female; Glucose Tolerance | 2006 |
Metabolic effects of a novel silicate inositol complex of the nitric oxide precursor arginine in the obese insulin-resistant JCR:LA-cp rat.
Topics: Animals; Arginine; Blood Glucose; Body Weight; Eating; Female; Inositol; Insulin; Insulin Resistance | 2007 |
Circulating factors and insulin resistance. I. A novel myoinositol 1,2-cyclic phosphate phosphoglycan insulin antagonist from human plasma is elevated in noninsulin-dependent diabetes mellitus.
Topics: Adipocytes; Adult; Animals; Chromatography, Gel; Cohort Studies; Diabetes Mellitus, Type 2; Female; | 1995 |
Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes.
Topics: Diabetes Mellitus, Type 2; Female; Gas Chromatography-Mass Spectrometry; Glucose Tolerance Test; Hum | 1994 |
chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Hemodialysis Solutions; Humans; Hydrogen-Ion Concent | 1993 |
Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys.
Topics: Analysis of Variance; Animals; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Hyperinsul | 1993 |
Chiroinositol deficiency and insulin resistance. II. Acute effects of D-chiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin-resistant rhesus monkeys.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Inositol; Insulin; | 1993 |
Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo.
Topics: Animals; Blood Glucose; Cattle; Diabetes Mellitus, Experimental; Glucose; Glycogen; Hydrogen-Ion Con | 1993 |
Effects of D-chiroinositol added to a meal on plasma glucose and insulin in hyperinsulinemic rhesus monkeys.
Topics: Animals; Blood Glucose; Food; Inositol; Insulin; Insulin Resistance; Kinetics; Macaca mulatta | 1995 |
Urinary myo-inositol-to-chiro-inositol ratios and insulin resistance.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gas Chromatography-Mass Spectrometry; Humans; | 1996 |
Dietary myoinositol results in lower urine glucose and in lower postprandial plasma glucose in obese insulin resistant rhesus monkeys.
Topics: Animals; Blood Glucose; Food, Fortified; Glycosuria; Inositol; Insulin; Insulin Resistance; Macaca m | 1996 |
The efficacy of voglibose on glycemic excursions in non-insulin-treated NIDDM patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; | 1998 |
Inositolphosphoglycans (IPGs) as mediators of insulin's steroidogenic actions.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inositol; Inositol Phosphat | 1998 |
Differential effects of troglitazone and D-chiroinositol on glucosamine-induced insulin resistance in vivo in rats.
Topics: Animals; Chromans; Glucosamine; Glucose Clamp Technique; Hypoglycemic Agents; Inositol; Insulin Resi | 1999 |
D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Glycogen Synthase; Inositol; Insulin; Insulin Res | 2002 |
D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Glycogen Synthase; Inositol; Insulin; Insulin Res | 2002 |
D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Glycogen Synthase; Inositol; Insulin; Insulin Res | 2002 |
D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Glycogen Synthase; Inositol; Insulin; Insulin Res | 2002 |
Pharmacological treatments for GH-induced insulin resistance.
Topics: Animals; Blood Gas Analysis; Blood Glucose; Chromans; Drug Interactions; Human Growth Hormone; Hypog | 1999 |
Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus.
Topics: Age Factors; Animals; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dogs; | 1990 |